v3.26.1
Insider Trading Arrangements
shares in Thousands
 3 Months Ended
Jun. 30, 2026
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

Rule 10b5-1 Trading Plans

During the three months ended June 30, 2026, the following directors and/or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” in each case as defined in Item 408 of Regulation S-K.

Character of Trading Arrangement

 

Action

Date of

Rule

Non-Rule

Nature of

Aggregate Number

 

 

Duration of Trading

Name and Title

Taken

Action

10b5-1*

10b5-1**

Trading

of Securities

 

 

Arrangement(1)

Amy Bachrodt, SVP, Finance(2)

Terminated

April 28, 2026

X

 

Sale

 

56,000

 

 

12/29/2025-12/31/2026

*Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

**"Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.

1 The trading arrangement may expire on an earlier date if and when all transactions under the arrangement are completed.

2 Amy Bachrodt resigned as SVP, Finance of Maze Therapeutics, Inc. (the “Company”), effective June 1, 2026.
Amy Bachrodt  
Trading Arrangements, by Individual  
Name Amy Bachrodt
Title SVP, Finance
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated true
Non-Rule 10b5-1 Arrangement Terminated false
Termination Date April 28, 2026
Expiration Date 12/31/2026
Arrangement Duration 367 days
Aggregate Available 56